Morgan Stanley Sio Gene Therapies Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.28 - $0.44 $420,000 - $660,000	1,500,000 Added 12116.32%	1,512,380 $665,000
Q3 2022 Nov 14, 2022	SELL	$0.28 - $0.41 $0 - $0	-1 Reduced 0.01%	12,380 $4,000
Q2 2022 Oct 27, 2022	SELL	$0.25 - $0.73 $1,218 - $3,557	-4,873 Reduced 28.24%	12,381 $4,000
Q2 2022 Aug 15, 2022	SELL	$0.25 - $0.73 $1,218 - $3,557	-4,873 Reduced 28.24%	12,381 $4,000
Q1 2022 Oct 27, 2022	BUY	$0.55 - $1.47 $2,680 - $7,163	4,873 Added 39.36%	17,254 $12,000
Q1 2022 May 13, 2022	SELL	$0.55 - $1.47 $463 - $1,237	-842 Reduced 4.65%	17,254 $12,000
Q4 2021 Feb 14, 2022	SELL	$1.29 - $2.36 $64,870 - $118,677	-50,287 Reduced 73.54%	18,096 $24,000
Q3 2021 Nov 15, 2021	BUY	$1.81 - $2.7 $123,773 - $184,634	68,383 New	68,383 $149,000

147K

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.